Intervention Review

Cabergoline for preventing ovarian hyperstimulation syndrome

  1. Huilin Tang1,*,
  2. Tamara Hunter2,
  3. Yongfang Hu1,
  4. Suo-Di Zhai1,
  5. Xiaoyan Sheng3,
  6. Roger J Hart4

Editorial Group: Cochrane Menstrual Disorders and Subfertility Group

Published Online: 15 FEB 2012

Assessed as up-to-date: 2 SEP 2011

DOI: 10.1002/14651858.CD008605.pub2


How to Cite

Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD008605. DOI: 10.1002/14651858.CD008605.pub2.

Author Information

  1. 1

    Peking University Third Hospital, Department of Pharmacy, Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University, Beijing, China

  2. 2

    King Edward Memorial Hospital, Department of Obstetrics and Gynaecology, Perth, Western Austraila, Australia

  3. 3

    Peking University Third Hospital.Beijing, Department of Pharmacy, Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University, Beijing, China

  4. 4

    The University of Western Australia, King Edward Memorial Hospital and Fertility Specialists of Western Australia, School of Women's and Infants Health, Subiaco, Western Australia, Australia

*Huilin Tang, Department of Pharmacy, Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University, Peking University Third Hospital, 49 North Garden Rd, Haidian District, Beijing, 100191, China. hltang1985@yahoo.cn.

Publication History

  1. Publication Status: New
  2. Published Online: 15 FEB 2012

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kathryn Coyne, MacKenzie Purdy, Kathleen O’Leary, Jerome L. Yaklic, Steven R. Lindheim, Leslie A. Appiah, Challenges and Considerations in Optimizing Ovarian Stimulation Protocols in Oncofertility Patients, Frontiers in Public Health, 2014, 2,

    CrossRef

  2. 2
    Mausumi Das, Weon-Young Son, William Buckett, Togas Tulandi, Hananel Holzer, In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome, Reproductive BioMedicine Online, 2014, 29, 5, 545

    CrossRef

  3. You have free access to this content3
    W. P. Martins, C. V. R. Vieira, D. M. Teixeira, M. A. P. Barbosa, L. A. Dassunção, C. O. Nastri, Ultrasound for monitoring controlled ovarian stimulation: a systematic review and meta-analysis of randomized controlled trials, Ultrasound in Obstetrics & Gynecology, 2014, 43, 1
  4. 4
    Manuel Fernández-Sánchez, Per Broberg, Göran Pettersson, Cristiano Busso, Antonio Pellicer, Joan-Carles Arce, Pre-hCG variables associated with occurrence of ascites in IVF/ICSI patients at moderate risk of developing OHSS: A pilot investigation, Open Journal of Obstetrics and Gynecology, 2013, 03, 01, 13

    CrossRef

  5. 5
    Cindy Farquhar, Josephine R Rishworth, Julie Brown, Willianne LDM Nelen, Jane Marjoribanks, Assisted reproductive technology: an overview of Cochrane Reviews, The Cochrane Library,
  6. 6
    Cindy Farquhar, Josephine R Rishworth, Julie Brown, Willianne LDM Nelen, Jane Marjoribanks, Assisted reproductive technology: an overview of Cochrane Reviews, The Cochrane Library,